Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial
Hackensack, NJ – December 10, 2013 – Champions Oncology (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.
The research trial is designed to validate the predictability and utility of the Champions TumorGraft™ platform in various types of breast cancer and will provide greater insight into personalized cancer therapy. 30 patients are expected to enroll in the study.
Following a procedure conducted at Monmouth Medical Center in Long Branch, NJ, the patient’s tumor was successfully implanted in a mouse avatar model utilizing Champions’ TumorGraft™ platform for personalized cancer therapy. Upon enrollment in the research trial, current and future trial participants will receive TumorGraft implanting, testing and recommendations.
Inclusion in the clinical trial is open to patients requiring surgical removal of a malignant breast tumor, and must meet one of the following criteria :
- Breast cancer that has spread (metastasized) to a different part of the body
- The tumor initially tested negative for ER, PR, and HER2
- The tumor initially tested positive for HER2
- The tumor was treated with chemotherapy prior to surgery and remains malignant
For more information on the trial or to apply to participate, contact Kimberly Chow at the Leon Hess Cancer Center’s Oncology Clinical Research Program, 732-923-6564.